FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2951387792> ?p ?o ?g. }

• W2951387792 abstract "Background: The basis of treatment of SLE are glucocorticoids (GCs), which since their introduction into clinical practice, have led to increased survival and reduced early mortality of SLE patients. However, the need to use high doses of GCs, as well as long-term use of medium doses to maintain disease remission, leads to the development of serious adverse reactions. This leads to an increase in the risk of irreversible organ damage. In this regard, it is important to search for ways to prevent the use of high doses of GCs, minimizing the dose of GCs. Objectives: To assess special aspects and dynamics of oral glucocorticoid (GC) therapy in SLE patients treated with anti-B-cell and anti-BlyS therapy. Methods: The study included 64 SLE pts (5М/58F), divided into 3 groups: Group I - 47 patients (SLEDAI2K 16[11;20] scores), receiving rituximab (RTX) i/v infusions by drop at 500 - 2000 mg dose-range. Group II included 10 patients (SLEDAI2K 10[8;11] scores) treated with Belimumab (BLM) at 10 mg/kg once a month. The remaining 7 patients from Group III (SLEDAI2K 10[9;16] scores) were administered a combination of RTX and BLM. They started treatment with RTX 500 (2 patients) or 1000 mg (5 patients) infusions, and 3 months later BLM at standard scheme of 10 mg/kg once a month was initiated for 8 months. SLICC damage index (DI) was documented at baseline - before initiation of RTX and BLM - in 26 out of 64 patients (40%) with SLICC DI score > 1 (1 - 5 scores); 20 patients out of them were administered RTX. Results: 47 patients on RTX therapy received different oral GCs doses: high GCs doses (Me 40[30;50]mg/day) were documented in 11 (24%) patients, moderate doses (Me 13[10;20]mg/day) – in 29 (61%) patients, and low doses (Me 5[5;7,5]mg/day) - in 7 (15%) patients. Patients on BLM and combination therapy were administered GCs at doses ≤ 20 mg (Me 15[5;20]mg/day and Me 8,75[5;15] mg/day, respectively) During first 3 month of treatment GCs doses in all 3 Groups remained unmodified. By Mo 6 25% reduction in oral GCs doses was documented in: patients on RTX - 20[15;20]mg/day, 10[8,75;10]mg/day, 5[5;5] mg/day (respectively, in the groups with initially high, moderate and low GCs doses); BLM 10[7,5;10] mg/day, combination therapy 8,75[5;15] mg/day. By Mo 12 Me GCs dose in all 3 Groups did not exceed 10 mg/day. In view of SLE exacerbations in patients from Group I (RTX) additional RTX infusions at Mo 6, 9 and 12 were administered in 8 (20%) patients. Figure 1 presents the dynamics of oral GCs doses in patients from Group I (RTX), who were divided in 3 subgroups based on baseline (high, moderate or low) GCs dose, and also dynamics of GCs dose in patients from Groups II (BLM) and III (RTX+BLM). Increase in SLICC score by Mo 12 of follow up was documented in patients on RTX therapy with baseline pre-existing organ damage (5 patients). There was no increase in SLICC scores in BLM and RTX+BLM treatment groups. Conclusion: Combination therapy results in achieving rapid control of SLE activity thanks to RTX effects, and the combination with BLM allows significantly prolongs this result, minimizing the risk of exacerbation. And a very specific gain from combination RTX+BLM therapy is a chance to manage patients on moderate-to-low oral GCs doses, therefore, reducing the risk of irreversible organ damage. Increasing organ damage score in RTX Group is most likely associated with intake of higher GCs doses. Disclosure of Interests: Anna Mesnyankina: None declared, Sergey Solovyev: None declared, Elena Aseeva: None declared, Evgeny Nasonov Speakers bureau: Pfizer, Inc., MSD, Novartis, AbbVie Inc., Celgen Corporation, Biocad, Janssen, UCB, Inc." @default.
• W2951387792 created "2019-06-27" @default.
• W2951387792 creator A5053399063 @default.
• W2951387792 creator A5072166059 @default.
• W2951387792 creator A5073796892 @default.
• W2951387792 creator A5074452337 @default.
• W2951387792 date "2019-06-01" @default.
• W2951387792 modified "2023-09-24" @default.
• W2951387792 title "AB0476 SPECIAL ASPECTS OF GLUCOCORTICOID THERAPY IN PATIENTS WHO TREATED WITH ANTI-B-CELL AND ANTI-BLYS THERAPY" @default.
• W2951387792 doi "https://doi.org/10.1136/annrheumdis-2019-eular.4294" @default.
• W2951387792 hasPublicationYear "2019" @default.
• W2951387792 type Work @default.
• W2951387792 sameAs 2951387792 @default.
• W2951387792 citedByCount "0" @default.
• W2951387792 crossrefType "proceedings-article" @default.
• W2951387792 hasAuthorship W2951387792A5053399063 @default.
• W2951387792 hasAuthorship W2951387792A5072166059 @default.
• W2951387792 hasAuthorship W2951387792A5073796892 @default.
• W2951387792 hasAuthorship W2951387792A5074452337 @default.
• W2951387792 hasBestOaLocation W29513877921 @default.
• W2951387792 hasConcept C126322002 @default.
• W2951387792 hasConcept C141071460 @default.
• W2951387792 hasConcept C159654299 @default.
• W2951387792 hasConcept C170286685 @default.
• W2951387792 hasConcept C197934379 @default.
• W2951387792 hasConcept C203014093 @default.
• W2951387792 hasConcept C2778453870 @default.
• W2951387792 hasConcept C2779338263 @default.
• W2951387792 hasConcept C2780653079 @default.
• W2951387792 hasConcept C2780841215 @default.
• W2951387792 hasConcept C2781205201 @default.
• W2951387792 hasConcept C71924100 @default.
• W2951387792 hasConcept C90924648 @default.
• W2951387792 hasConceptScore W2951387792C126322002 @default.
• W2951387792 hasConceptScore W2951387792C141071460 @default.
• W2951387792 hasConceptScore W2951387792C159654299 @default.
• W2951387792 hasConceptScore W2951387792C170286685 @default.
• W2951387792 hasConceptScore W2951387792C197934379 @default.
• W2951387792 hasConceptScore W2951387792C203014093 @default.
• W2951387792 hasConceptScore W2951387792C2778453870 @default.
• W2951387792 hasConceptScore W2951387792C2779338263 @default.
• W2951387792 hasConceptScore W2951387792C2780653079 @default.
• W2951387792 hasConceptScore W2951387792C2780841215 @default.
• W2951387792 hasConceptScore W2951387792C2781205201 @default.
• W2951387792 hasConceptScore W2951387792C71924100 @default.
• W2951387792 hasConceptScore W2951387792C90924648 @default.
• W2951387792 hasLocation W29513877921 @default.
• W2951387792 hasOpenAccess W2951387792 @default.
• W2951387792 hasPrimaryLocation W29513877921 @default.
• W2951387792 hasRelatedWork W1927466229 @default.
• W2951387792 hasRelatedWork W2141044946 @default.
• W2951387792 hasRelatedWork W2290560590 @default.
• W2951387792 hasRelatedWork W2317217511 @default.
• W2951387792 hasRelatedWork W2323862721 @default.
• W2951387792 hasRelatedWork W2366401729 @default.
• W2951387792 hasRelatedWork W2411522465 @default.
• W2951387792 hasRelatedWork W2558944703 @default.
• W2951387792 hasRelatedWork W2559223451 @default.
• W2951387792 hasRelatedWork W2559743688 @default.
• W2951387792 hasRelatedWork W2559756542 @default.
• W2951387792 hasRelatedWork W2590859321 @default.
• W2951387792 hasRelatedWork W2950226825 @default.
• W2951387792 hasRelatedWork W3029577887 @default.
• W2951387792 hasRelatedWork W3029850653 @default.
• W2951387792 hasRelatedWork W3128714093 @default.
• W2951387792 hasRelatedWork W3134808072 @default.
• W2951387792 hasRelatedWork W3164825194 @default.
• W2951387792 hasRelatedWork W3165884734 @default.
• W2951387792 hasRelatedWork W384719535 @default.
• W2951387792 isParatext "false" @default.
• W2951387792 isRetracted "false" @default.
• W2951387792 magId "2951387792" @default.
• W2951387792 workType "article" @default.